Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment

Zhu, Yingze; Cui, Yishuang; Zheng, Xuan; Zhao, Yue; Sun, Guogui

doi:10.1016/j.bbadis.2022.166557

Cited by 26 publications

(16 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alarmingly, the median overall survival for SCLC patients with brain metastases is a mere 4.9 months. [37,38] To a large extent, patients afflicted with SCLC and brain metastases frequently experience compromised neurological function. And symptoms such as cerebral edema and increased intracranial pressure further contribute to the complexity and severity of their condition.…”

Section: Discussionmentioning

confidence: 99%

A practical nomogram for predicting early death in elderly small cell lung cancer patients: A SEER-based study

Chen,

Liu,

Tou

et al. 2024

Medicine

View full text Add to dashboard Cite

This study aimed to identify risk factors for early death in elderly small cell lung cancer (SCLC) patients and develop nomogram prediction models for all-cause and cancer-specific early death to improve patient management. Data of elderly patients diagnosed with SCLC were extracted from the SEER database, then randomly divided into training and validation cohorts. Univariate and stepwise multivariable Logistic regression analyses were performed on the training cohort to identify independent risk factors for early death in these patients. Nomograms were developed based on these factors to predict the overall risk of early death. The efficacy of the nomograms was validated using various methods, including ROC analysis, calibration curves, DCA, NRI, and IDI. Among 2077 elderly SCLC patients, 773 died within 3 months, 713 due to cancer-specific causes. Older age, higher AJCC staging, brain metastases, and lack of surgery, chemotherapy, or radiotherapy increase the risk of all-cause early death, while higher AJCC staging, brain metastases, lung metastases, and lack of surgery, chemotherapy, or radiotherapy increase the risk of cancer-specific death (P < .05). These identified factors were used to construct 2 nomograms to predict the risk of early death. The ROC indicated that the nomograms performed well in predicting both all-cause early death (AUC = 0.823 in the training cohort and AUC = 0.843 in the validation cohort) and cancer-specific early death (AUC = 0.814 in the training cohort and AUC = 0.841 in the validation cohort). The results of calibration curves, DCAs, NRI and IDI also showed that the 2 sets of nomograms had good predictive power and clinical utility and were superior to the commonly used TNM staging system. The nomogram prediction models constructed in this study can effectively assist clinicians in predicting the risk of early death in elderly SCLC patients, and can also help physicians screen patients at higher risk and develop personalized treatment plans for them.

show abstract

Section: Discussionmentioning

confidence: 99%

A practical nomogram for predicting early death in elderly small cell lung cancer patients: A SEER-based study

Chen,

Liu,

Tou

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…The development of LUAD is determined by the build-up of mutations in numerous genes, leading to the unchecked proliferation of tumors. A considerable proportion of patients receive a diagnosis in advanced stages, presenting significant problems for both patients and healthcare providers (Zhu et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Oxyepiberberine from the Active Site of Coptidis Rhizoma Inhibits Lung Adenocarcinoma by Regulating SRC-related Pathways in vivo

Zhang,

Xue,

Zeng

et al. 2024

Pharmacognosy Magazine

View full text Add to dashboard Cite

Background: Huanglian (HL), also known as Coptis chinensis Franch., was initially documented in “Sheng Nong’s Herbal Classic” as a high-quality product used to cure ailments such as fever, indigestion, bloating, nausea, dysentery, diarrhea, abdominal pain, and tuberculosis. Nowadays, it is extensively employed in clinical settings to alleviate pulmonary diseases, like tuberculosis, lobular lung disease, and pulmonary abscess, and is worth exploring further. Nevertheless, there is limited research on the precise advancements of anti-lung adenocarcinoma (LUAD). Objectives: Using biological experiments and network pharmacology, the objective of this research was to investigate the most effective parts and chemical constituents of C. chinensis against LUAD and ascertain the probable targets and pathways. Materials and Methods: First, an MTT experiment verified the impact of each part on A549 and BEAS-2B cells. High performance liquid chromatography (HPLC) was then used to identify the chemical components of the effective substance in C. chinensis against LUAD. Then, network pharmacology was used to screen potential pathways and binding target proteins. Finally, a subcutaneous tumor model was established in mice using LLC cells to observe the effects of the effective components of C. chinensis against LUAD in tumor-bearing mice. Results: The MTT assay demonstrated the efficacy of oxyepiberberine (OPB) as an anti-LUAD compound with minimal toxicity and side effects. According to the results of network pharmacology and molecular docking, SRC appears to be the primary target of C. chinensis active substance against LUAD. In vivo experiments revealed that the OPB group exhibited lowered toxicity and side effects. Additionally, the density of tumor cells decreased and the nuclei were destroyed in OPB groups of tumor tissues. Finally, OPB could regulate apoptosis, migration, and protein expression significantly related to the SRC pathway in tumor cells. Conclusion: Our research reveals the anti-LUAD properties of C. chinensis through a combination of experimentation and network analysis. These findings establish a theoretical foundation for C. chinensis as a clinical antitumor agent. Furthermore, our work provided an essential groundwork for further investigations into the medicinal properties of C. chinensis.

show abstract

“…Cancer has become a leading cause of death worldwide, responsible for millions of deaths yearly, [1–4] and the latest oncology reports have also approved these incidents [5–8] . We are forced to accept the fact that tens of millions of people die every year from cancer disease in the world.…”

Section: Introductionmentioning

confidence: 99%

Furo[2,3‐d]pyrimidines as Mackinazolinone/Isaindigotone Analogs: Synthesis, Modification, Antitumor Activity, and Molecular Docking Study

Song

Nie

Bozorov

et al. 2023

Chemistry & Biodiversity

View full text Add to dashboard Cite

The chemical transformation of the tricyclic furo[2,3‐d]pyrimidines was performed under isosteric and scaffold‐hopping strategies focusing on the synthesis of its arylidene and imine‐containing derivatives. Naturally‐occurring alkaloids mackinazolinone and isaindigotone were as templates of target heterocycles. Synthesized compounds evaluated for their antitumor activity on human cancer cervical HeLa, breast MCF‐7, and colon HT‐29 cell lines. Four compounds: 8c, 8e, 10b, and 10c demonstrated potency against HeLa and HT‐29 cell lines, and IC50 values were between 7.37–13.72 μM, respectively. The molecular docking results showed that compounds 8c and 10b had good binding and high matching with the target EGFR protein.

show abstract

Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment

Cited by 26 publications

References 134 publications

A practical nomogram for predicting early death in elderly small cell lung cancer patients: A SEER-based study

A practical nomogram for predicting early death in elderly small cell lung cancer patients: A SEER-based study

Oxyepiberberine from the Active Site of Coptidis Rhizoma Inhibits Lung Adenocarcinoma by Regulating SRC-related Pathways in vivo

Furo[2,3‐d]pyrimidines as Mackinazolinone/Isaindigotone Analogs: Synthesis, Modification, Antitumor Activity, and Molecular Docking Study

Contact Info

Product

Resources

About